California’s stem cell agency has appointed a contract research and consulting company to run its preclinical acceleration program.
The so-called translating center will help researchers move their stem cell work towards a clinical trial faster. It’s part of the California Institute for Regenerative Medicine’s CIRM 2.0 strategy unveiled in November 2015. The agency has promised to halve the time it takes to get drug candidates into clinical trials.
“Today it takes about eight years to move a promising stem cell treatment from the lab into human trials. That’s eight years many people with serious disease don’t have,” said CIRM president Randal Mills.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.